IMDX — Insight Molecular Diagnostics Share News
0.000.00%
Last trade - 00:00- $92.61m
- $75.62m
- $4.06m
Insight Molecular Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a share - Earnings Preview
Insight Molecular Diagnostics Q1 loss narrows as costs drop
Brief: Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission
Brief: Insight Molecular Diagnostics Enters Agreement With Quest Diagnostics - SEC Filing
Brief: Imdx Announces $26.0 Million Registered Direct Offering
Brief: Imdx Welcomes New VP Marketing To Prepare For Commercial Transplant Assay Launch
Brief: Imdx Reports kidney transplant patient achieved ‘immune reset’ with novel therapy and graftassure monitoring
Brief: IMDX Enrolls First Patient In Graftassuredx Clinical Trial And Welcomes New Hospital Participants
Insight Molecular Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary
Insight Molecular Diagnostics Inc expected to post a loss of 23 cents a share - Earnings Preview
Insight Molecular Diagnostics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: iMDx Reports Strong Head-To-Head Data In Kidney Transplant Rejection Testing
Brief: Oncocyte Changes Name To Insight Molecular Diagnostics
Brief: Oncocyte Corp Says New CMS Reimbursement Price Rate Of $2,753 Per Result For Graftassurecore Assay
OncoCyte Corp reports results for the quarter ended March 31 - Earnings Summary
OncoCyte Corp expected to post a loss of 24 cents a share - Earnings Preview
Brief: Oncocyte Provides Positive Update On Clinical Trial ProgresS
OncoCyte Corp expected to post a loss of 43 cents a share - Earnings Preview